Literature DB >> 12208228

Efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias in patients with life-threatening ventricular tachyarrhythmias.

R Ricci1, C Pignalberi, M Disertori, A Capucci, L Padeletti, G Botto, S Toscano, F Miraglia, A Grammatico, M Santini.   

Abstract

BACKGROUND: Atrial fibrillation has a high incidence in patients wearing an implantable cardioverter defibrillator for ventricular tachyarrhythmias and may lead to palpitations, heart failure, angina, stroke and inappropriate defibrillator discharge. The aim of the study was to evaluate the efficacy of a dual chamber defibrillator with atrial antitachycardia functions in treating spontaneous atrial tachyarrhythmias.
METHODS: One hundred and twelve patients, 88 male, mean age 64+/-11 years, were enrolled. Seventy-six had ischaemic heart disease, 21 idiopathic dilated cardiomyopathy, nine other heart diseases, six no structural heart disease. The mean left ventricular ejection fraction was 40+/-11%. Sixty-two had prior atrial tachyarrhythmias.
RESULTS: Follow-up lasted 11+/-9 months (range 1-42). Among 933 ventricular tachyarrhythmia episodes, 100% of ventricular fibrillation and 92% of ventricular tachycardia were successfully cardioverted. Among 414 detected sustained atrial tachyarrhythmias, 195 were classified as atrial tachycardia (47.1%), 192 as atrial fibrillation (46.4%) and 27 (6.5%) as sinus rhythm. The detection-positive predictive value was 93.5%. Therapy success rates: antitachy pacing on atrial tachycardia = 71.3% (crude estimate); 66.1% (adjusted estimate); 50 Hertz on atrial fibrillation=36.2% (crude estimate); 13.5% (adjusted estimate); atrial shock on atrial fibrillation = 62.5% (mean energy 7.8+/-14.1J). Shock efficacy was 32% when delivered energy was < or = 2 atrial defibrillation threshold at implant and 92% when >2. Duration of successfully treated atrial episodes was significantly lower than that of unsuccessfully treated (6+/-26 min vs 42+/-60).
CONCLUSIONS: Atrial antitachy pacing and shock therapies demonstrated very high efficacy in treating atrial tachyarrhythmias in defibrillator patients. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12208228     DOI: 10.1053/euhj.2001.3154

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  12 in total

1.  Implantable defibrillators configured for hybrid therapy of persistent and permanent atrial fibrillation: initial clinical experience with a novel lead system.

Authors:  Hygriv B Rao; Sanjeev Saksena
Journal:  J Interv Card Electrophysiol       Date:  2005-08       Impact factor: 1.900

2.  Is dual defibrillator better than conventional DDD pacing in brady-tachy syndrome? Results of the ICARUS Trial (Internal Cardioversion Antitachypacing and Prevention: Resource Utilization Study).

Authors:  Massimo Santini; Renato Ricci; Carlo Pignalberi; Maurizio Russo; Barbara Magris; Nicoletta Grovale; Tiziana De Santo
Journal:  J Interv Card Electrophysiol       Date:  2006-01-18       Impact factor: 1.900

3.  Dual defibrillator improves quality of life and decreases hospitalizations in patients with drug refractory atrial fibrillation.

Authors:  Renato Ricci; Aurelio Quesada; Carlo Pignalberi; Josè Roda; Marcello Disertori; Alessandro Capucci; Antonio Raviele; Massimo Santini
Journal:  J Interv Card Electrophysiol       Date:  2004-02       Impact factor: 1.900

Review 4.  Atrial fibrillation: the role of atrial defibrillation.

Authors:  Massimo Santini; Renato Ricci
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

Review 5.  Rationale and patient selection for "hybrid" drug and device therapy in atrial and ventricular arrhythmias.

Authors:  A John Camm; Irina Savelieva
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

6.  Termination of atrial fibrillation using pulsed low-energy far-field stimulation.

Authors:  Flavio H Fenton; Stefan Luther; Elizabeth M Cherry; Niels F Otani; Valentin Krinsky; Alain Pumir; Eberhard Bodenschatz; Robert F Gilmour
Journal:  Circulation       Date:  2009-07-27       Impact factor: 29.690

7.  Treatment of atrial fibrillation with a dual defibrillator in heart failure patients (TRADE HF): protocol for a randomized clinical trial.

Authors:  Giovanni Luca Botto; Giuseppe Boriani; Stefano Favale; Maurizio Landolina; Giulio Molon; Claudio Tondo; Mauro Biffi; Giuseppe Grandinetti; Paolo De Filippo; Giovanni Raciti; Luigi Padeletti
Journal:  Trials       Date:  2011-02-15       Impact factor: 2.279

Review 8.  The worldwide social burden of atrial fibrillation: what should be done and where do we go?

Authors:  Massimo Santini; Renato P Ricci
Journal:  J Interv Card Electrophysiol       Date:  2007-03-20       Impact factor: 1.759

9.  Selecting dual chamber or single chamber implantable defibrillators: what is the golden rule?

Authors:  Massimo Santini; Renato Ricci
Journal:  Indian Pacing Electrophysiol J       Date:  2003-10-01

10.  Atrial fibrillation and pacing algorithms.

Authors:  Paolo Terranova; Barbara Severgnini; Paolo Valli; Simonetta Dell'Orto; Enrico Maria Greco
Journal:  Indian Pacing Electrophysiol J       Date:  2006-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.